<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JAMA Health Forum</journal-id><journal-id journal-id-type="iso-abbrev">JAMA Health Forum</journal-id><journal-id journal-id-type="pmc-domain-id">3211</journal-id><journal-id journal-id-type="pmc-domain">jamasd</journal-id><journal-title-group><journal-title>JAMA Health Forum</journal-title></journal-title-group><issn pub-type="epub">2689-0186</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>JAMA Network</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12035657</article-id><article-id pub-id-type="pmcid-ver">PMC12035657.1</article-id><article-id pub-id-type="pmcaid">12035657</article-id><article-id pub-id-type="pmcaiid">12035657</article-id><article-id pub-id-type="pmid">40287986</article-id><article-id pub-id-type="doi">10.1001/jamahealthforum.2025.1814</article-id><article-id pub-id-type="publisher-id">aoi250039</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="category" specific-use="electronic"><subject>Research</subject></subj-group><subj-group subj-group-type="domain" specific-use="print"><subject>Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Investigation</subject></subj-group><subj-group subj-group-type="online-only"><subject>Online Only</subject></subj-group><subj-group subj-group-type="allowCommenting"><subject>Comments</subject></subj-group></article-categories><title-group><article-title>Buprenorphine Treatment in Pregnancy and Maternal-Infant Outcomes</article-title><alt-title alt-title-type="headline">Buprenorphine Treatment in Pregnancy and Maternal-Infant Outcomes</alt-title><alt-title alt-title-type="running-head">Buprenorphine Treatment in Pregnancy and Maternal-Infant Outcomes</alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Krishnapura</surname><given-names initials="SR">Sunaya R.</given-names></name><degrees>BA</degrees><xref rid="aoi250039aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>McNeer</surname><given-names initials="E">Elizabeth</given-names></name><degrees>MS</degrees><xref rid="aoi250039aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Loch</surname><given-names initials="SF">Sarah F.</given-names></name><degrees>MPH</degrees><xref rid="aoi250039aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Reese</surname><given-names initials="T">Thomas</given-names></name><degrees>PharmD</degrees><degrees>PhD</degrees><xref rid="aoi250039aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dudley</surname><given-names initials="J">Judith</given-names></name><degrees>BS</degrees><xref rid="aoi250039aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Phillippi</surname><given-names initials="JC">Julia C.</given-names></name><degrees>PhD</degrees><degrees>CNM</degrees><xref rid="aoi250039aff6" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wiese</surname><given-names initials="AD">Andrew D.</given-names></name><degrees>PhD</degrees><degrees>MPH</degrees><xref rid="aoi250039aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dupont</surname><given-names initials="WD">William D.</given-names></name><degrees>PhD</degrees><xref rid="aoi250039aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Leech</surname><given-names initials="AA">Ashley A.</given-names></name><degrees>PhD</degrees><xref rid="aoi250039aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Patrick</surname><given-names initials="SW">Stephen W.</given-names></name><degrees>MD</degrees><degrees>MPH</degrees><degrees>MS</degrees><xref rid="aoi250039aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aoi250039aff7" ref-type="aff">
<sup>7</sup>
</xref><xref rid="aoi250039aff8" ref-type="aff">
<sup>8</sup>
</xref></contrib></contrib-group><aff id="aoi250039aff1"><label>1</label>Vanderbilt University School of Medicine, Nashville, Tennessee</aff><aff id="aoi250039aff2"><label>2</label>Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee</aff><aff id="aoi250039aff3"><label>3</label>Department of Health Policy and Management, Rollins School of Public Health, Emory University, Atlanta, Georgia</aff><aff id="aoi250039aff4"><label>4</label>Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee</aff><aff id="aoi250039aff5"><label>5</label>Department of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee</aff><aff id="aoi250039aff6"><label>6</label>Vanderbilt University School of Nursing, Nashville, Tennessee</aff><aff id="aoi250039aff7"><label>7</label>Division of Neonatology, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia</aff><aff id="aoi250039aff8"><label>8</label>Health Services Research Center, Emory University, Atlanta, Georgia</aff><author-notes><title>Article Information</title><p><bold>Accepted for Publication:</bold> April 10, 2025.</p><p content-type="published-online"><bold>Published:</bold> April 27, 2025. doi:<uri content-type="doi">10.1001/jamahealthforum.2025.1814</uri></p><p content-type="open-access-note"><bold>Open Access:</bold> This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://jamanetwork.com/pages/cc-by-license-permissions" ext-link-type="uri">CC-BY License</ext-link>. &#169; 2025 Krishnapura SR et al. <italic toggle="yes">JAMA Health Forum</italic>.</p><corresp id="aoi250039cor1"><bold>Corresponding Author:</bold> Stephen W. Patrick, MD, MPH, MS, Department of Health Policy and Management, Rollins School of Public Health, Emory University, GCR-HPM, 1518 Clifton Rd NE, 6th Floor, Atlanta, GA 30322 (<email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="stephen.patrick@emory.edu">stephen.patrick@emory.edu</email>).</corresp><p content-type="author-contributions"><bold>Author Contributions:</bold> Dr Patrick had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p><p><italic toggle="yes">Concept and design:</italic> Krishnapura, Phillippi, Wiese, Patrick.</p><p><italic toggle="yes">Acquisition, analysis, or interpretation of data:</italic> All authors.</p><p><italic toggle="yes">Drafting of the manuscript:</italic> Krishnapura.</p><p><italic toggle="yes">Critical review of the manuscript for important intellectual content:</italic> All authors.</p><p><italic toggle="yes">Statistical analysis:</italic> McNeer, Wiese, Dupont, Patrick.</p><p><italic toggle="yes">Obtained funding:</italic> Patrick.</p><p><italic toggle="yes">Administrative, technical, or material support:</italic> Loch, Reese, Dudley, Phillippi, Wiese, Leech, Patrick.</p><p><italic toggle="yes">Supervision:</italic> Reese, Phillippi, Patrick.</p><p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> Dr Reese reported grants from the National Institutes of Health and the Agency for Healthcare Research and Quality during the conduct of the study. Dr Phillippi reported grants from the Health Resources and Services Administration, travel fees from the American College of Nurse-Midwives, and royalties from Jones &amp; Bartlett Learning for the <italic toggle="yes">Varney&#8217;s Midwifery </italic>textbook outside the submitted work. Dr Wiese reported grants from the National Institutes of Health during the conduct of the study. Dr Dupont reported grants from the National Institutes of Health during the conduct of the study and outside the submitted work. Dr Patrick reported grants from the National Institute on Drug Abuse, the Agency for Healthcare Research and Quality, the Center for Medicare and Medicaid Innovation, and the Boedecker Foundation outside the submitted work. No other disclosures were reported.</p><p content-type="funding-statement"><bold>Funding/Support:</bold> Research reported in this publication was supported by the National Institute on Child Health and Human Development under award number P50HD106446 (Dr Patrick).</p><p><bold>Role of the Funder/Sponsor:</bold> The National Institute on Child Health and Human Development had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p><p><bold>Disclaimer:</bold> The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.</p><p><bold>Meeting Presentation:</bold> This study was presented at the Pediatric Academic Society Annual Meeting; April 27, 2025; Honolulu, Hawaii.</p><p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-AOI250039-1-s" ref-type="supplementary-material">Supplement 2</xref>.</p></author-notes><pub-date pub-type="epub" iso-8601-date="2025-04-27T15:45"><day>27</day><month>4</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2025</year></pub-date><volume>6</volume><issue>4.11</issue><issue-id pub-id-type="pmc-issue-id">487458</issue-id><elocation-id>e251814</elocation-id><history><date date-type="received"><day>31</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>10</day><month>4</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>27</day><month>04</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>29</day><month>04</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-04-29 00:25:23.213"><day>29</day><month>04</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright 2025 Krishnapura SR et al. <italic toggle="yes">JAMA Health Forum</italic>.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the CC-BY License.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jamahealthforum-e251814.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf-version" xlink:href="jamahealthforum-e251814.pdf">jamahealthforum-e251814.pdf</self-uri><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="silverchair" xlink:href="https://jamanetwork.com/channels/health-forum/fullarticle/10.1001/jamahealthforum.2025.1814"/><abstract abstract-type="teaser" specific-use="electronic"><p>This cohort study aims to determine if treatment with buprenorphine among mothers with opioid use disorder in pregnancy is associated with improved maternal and infant outcomes compared to no treatment.</p></abstract><abstract abstract-type="key-points"><title>Key Points</title><sec id="ab-aoi250039-1"><title>Question</title><p>Does treatment with buprenorphine for opioid use disorder (OUD) in pregnancy improve maternal and infant outcomes?</p></sec><sec id="ab-aoi250039-2"><title>Findings</title><p>In this cohort study of 14&#8201;463 maternal-infant dyads, treatment with buprenorphine was associated with a lower probability of severe maternal morbidity, preterm birth, and neonatal intensive care unit admissions compared to no treatment.</p></sec><sec id="ab-aoi250039-3"><title>Meaning</title><p>Buprenorphine treatment for OUD during pregnancy was associated with improved outcomes for mothers and infants, highlighting the importance of treatment expansion in the US.</p></sec></abstract><abstract><sec id="ab-aoi250039-4"><title>Importance</title><p>Opioid use disorder (OUD) in pregnancy has grown in the US. Buprenorphine, a medication to treat OUD, may improve pregnancy outcomes; however, most pregnant individuals do not receive it. Research evaluating buprenorphine use in pregnancy, its effects on the maternal-infant dyad, and in comparison to no treatment is limited.</p></sec><sec id="ab-aoi250039-5"><title>Objective</title><p>To determine if treatment with buprenorphine for opioid use disorder in pregnancy is associated with improved maternal and infant outcomes compared to no treatment among mothers with OUD.</p></sec><sec id="ab-aoi250039-6"><title>Design, Setting, and Participants</title><p>This retrospective cohort study included maternal-infant dyads continuously enrolled in the Tennessee Medicaid program from 20 weeks&#8217; estimated gestational age to 6 weeks post partum between 2010 and 2021. Medicaid administrative was linked to birth and death certificates. Data analysis was conducted from April to October 2024.</p></sec><sec id="ab-aoi250039-7"><title>Exposure</title><p>Buprenorphine use during pregnancy.</p></sec><sec id="ab-aoi250039-8"><title>Main Outcomes and Measures</title><p>Adverse pregnancy outcomes included preterm birth, neonatal intensive care unit (NICU) admission, infant death, severe maternal morbidity (SMM), intensive care unit admission, and maternal death. Logistic regression and propensity scores with overlap weighting were used to calculate adjusted predicted probabilities for adverse outcomes.</p></sec><sec id="ab-aoi250039-9"><title>Results</title><p>Among 14&#8201;463 maternal-infant dyads, 7469 (51.6%) received buprenorphine treatment (median [IQR] maternal age, 27 [24-31] years). There was a statistically significant lower rate of adverse pregnancy outcomes among dyads treated with buprenorphine compared to untreated dyads (25.4% vs 30.8%; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;.001); the treatment group also had a lower rate of SMM events (5.4% vs 6.9%; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;.001), preterm births (14.1% vs 20.0%; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;.001), and NICU admissions (15.2% vs 17.2%; <italic toggle="yes">P</italic>&#8201;=&#8201;.001). In adjusted analyses, those with buprenorphine treatment had a 5.1 percentage point (pp; 95% CI, 3.5-6.7 pp) lower probability of any adverse outcomes, including a 1.2 pp (95% CI, 0.4-2.1 pp) lower probability of SMM, 1.7 pp (95% CI, 0.4-2.9 pp) lower probability of NICU admission, and 5.3 pp (95% CI, 4.0-6.6 pp) lower probability of preterm birth. The number needed to treat to avoid an adverse pregnancy outcome was 20.</p></sec><sec id="ab-aoi250039-10"><title>Conclusions and Relevance</title><p>In this cohort study of pregnant individuals with OUD, buprenorphine treatment was associated with improved outcomes for the mother and infant, underscoring the need to improve access to treatment nationwide.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="H1-1-AOI250039"><title>Introduction</title><p>The number of pregnant people with opioid use disorder (OUD) in the US has increased from 1.5 per 1000 delivery hospitalizations in 1999<sup><xref rid="aoi250039r1" ref-type="bibr">1</xref></sup> to 8.2 per 1000 delivery hospitalizations in 2017.<sup><xref rid="aoi250039r2" ref-type="bibr">2</xref></sup> Pregnant people with OUD are at risk for numerous adverse health outcomes, such as overdose,<sup><xref rid="aoi250039r3" ref-type="bibr">3</xref></sup> infection,<sup><xref rid="aoi250039r4" ref-type="bibr">4</xref></sup> severe maternal morbidity (SMM),<sup><xref rid="aoi250039r5" ref-type="bibr">5</xref>,<xref rid="aoi250039r6" ref-type="bibr">6</xref>,<xref rid="aoi250039r7" ref-type="bibr">7</xref></sup> postpartum readmission,<sup><xref rid="aoi250039r6" ref-type="bibr">6</xref></sup> and death.<sup><xref rid="aoi250039r8" ref-type="bibr">8</xref></sup> Additionally, opioid use in pregnancy has been associated with adverse fetal and neonatal outcomes, including fetal growth restriction,<sup><xref rid="aoi250039r8" ref-type="bibr">8</xref>,<xref rid="aoi250039r9" ref-type="bibr">9</xref></sup> preterm birth,<sup><xref rid="aoi250039r1" ref-type="bibr">1</xref>,<xref rid="aoi250039r4" ref-type="bibr">4</xref>,<xref rid="aoi250039r7" ref-type="bibr">7</xref>,<xref rid="aoi250039r8" ref-type="bibr">8</xref>,<xref rid="aoi250039r9" ref-type="bibr">9</xref></sup> stillbirth,<sup><xref rid="aoi250039r1" ref-type="bibr">1</xref>,<xref rid="aoi250039r4" ref-type="bibr">4</xref>,<xref rid="aoi250039r8" ref-type="bibr">8</xref>,<xref rid="aoi250039r9" ref-type="bibr">9</xref></sup> and death.<sup><xref rid="aoi250039r10" ref-type="bibr">10</xref></sup> While opioid agonist treatment with methadone or buprenorphine is widely recommended,<sup><xref rid="aoi250039r9" ref-type="bibr">9</xref></sup> many pregnant people do not receive this treatment.<sup><xref rid="aoi250039r11" ref-type="bibr">11</xref></sup></p><p>Methadone was the mainstay treatment for OUD until buprenorphine was approved by the US Food and Drug Administration in 2002.<sup><xref rid="aoi250039r12" ref-type="bibr">12</xref></sup> Methadone is a full &#956;-opioid receptor agonist, while buprenorphine is a partial &#956;-opioid receptor agonist and a full &#954;-receptor antagonist, giving buprenorphine a superior safety profile, including a lower risk of respiratory depression.<sup><xref rid="aoi250039r13" ref-type="bibr">13</xref></sup> The use of either medication is endorsed by the American College of Obstetrics and Gynecology<sup><xref rid="aoi250039r9" ref-type="bibr">9</xref></sup> and the Substance Abuse and Mental Health Administration<sup><xref rid="aoi250039r14" ref-type="bibr">14</xref></sup> to reduce the risk of overdose and improve pregnancy outcomes. Since its introduction in the US market, buprenorphine has become the dominant medication used to treat OUD nationwide, attributed mainly to state and federal policies.<sup><xref rid="aoi250039r15" ref-type="bibr">15</xref>,<xref rid="aoi250039r16" ref-type="bibr">16</xref></sup></p><p>Since buprenorphine&#8217;s adoption in the US, research on its use in pregnancy has focused on comparing its clinical outcomes with those of methadone.<sup><xref rid="aoi250039r17" ref-type="bibr">17</xref>,<xref rid="aoi250039r18" ref-type="bibr">18</xref></sup> In contrast, existing research comparing treatment to no treatment has been limited to analyses from methadone treatment in the 1970s.<sup><xref rid="aoi250039r4" ref-type="bibr">4</xref></sup> Furthermore, more recent secondary data analyses combined different types of pharmacotherapy for OUD with different mechanisms and have not accounted for treatment selection bias (ie, bias among groups that leads to treatment receipt) or evaluated maternal outcomes (eg, SMM) alongside matched infant outcomes.<sup><xref rid="aoi250039r19" ref-type="bibr">19</xref></sup> Nationwide, at least 50% of pregnant individuals with OUD do not receive treatment.<sup><xref rid="aoi250039r11" ref-type="bibr">11</xref></sup> Consequently, determining if buprenorphine in pregnancy improves pregnancy outcomes compared to no treatment is a highly relevant public health question that could inform public health programs and policy. To address this knowledge gap, we conducted a population-based study to test the hypothesis that among pregnant individuals with OUD, buprenorphine treatment in pregnancy compared to no treatment improves both maternal outcomes (SMM, intensive care unit [ICU] admission, and death) and infant outcomes (preterm birth, neonatal ICU [NICU] admission, and death).</p></sec><sec id="H1-2-AOI250039"><title>Methods</title><sec id="H2-1-AOI250039"><title>Data Source and Study Cohort</title><p>In this retrospective cohort analysis, we included maternal-infant dyads continuously enrolled in the Tennessee Medicaid (TennCare) program from 20 weeks&#8217; estimated gestational age (EGA) to 6 weeks post partum between 2010 and 2021. We linked Medicaid administrative data (outpatient, inpatient, and prescription claims) to birth and death certificates. These data have been used for prior analyses evaluating medication safety in pregnancy.<sup><xref rid="aoi250039r20" ref-type="bibr">20</xref>,<xref rid="aoi250039r21" ref-type="bibr">21</xref></sup> The study included pregnant people between ages 15 and 44 years with a diagnosis of OUD (evidence of &#8805;2 outpatient diagnoses or 1 inpatient diagnosis of OUD) or a filled buprenorphine prescription during pregnancy (20 weeks&#8217; gestation to birth) and their singleton fetuses/infants (eTable 1 in <xref rid="note-AOI250039-1-s" ref-type="supplementary-material">Supplement 1</xref>). We excluded pregnant people with methadone, naltrexone, or non-OUD buprenorphine prescriptions (eg, pain) during the study period. Covariates were identified from 20 weeks&#8217; EGA to birth, and outcomes were measured from birth to 6 weeks post partum.</p><p>This study was approved by the institutional review boards at Vanderbilt University Medical Center and the Tennessee Department of Health and received a nonhuman participants determination with waiver of informed consent. This study followed Strengthening the Reporting of Observational Studies in Epidemiology (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.equator-network.org/reporting-guidelines/strobe/" ext-link-type="uri">STROBE</ext-link>) reporting guidelines for cohort studies.</p></sec><sec id="H2-2-AOI250039"><title>Conceptual Model</title><p>OUD is associated with adverse outcomes for both pregnant individuals and their fetuses/infants (eFigure 1 in <xref rid="note-AOI250039-1-s" ref-type="supplementary-material">Supplement 1</xref>). Aside from diagnoses of neonatal opioid withdrawal syndrome (NOWS), adverse infant outcomes include preterm birth,<sup><xref rid="aoi250039r1" ref-type="bibr">1</xref>,<xref rid="aoi250039r4" ref-type="bibr">4</xref>,<xref rid="aoi250039r7" ref-type="bibr">7</xref>,<xref rid="aoi250039r8" ref-type="bibr">8</xref>,<xref rid="aoi250039r9" ref-type="bibr">9</xref></sup> fetal growth restriction,<sup><xref rid="aoi250039r8" ref-type="bibr">8</xref>,<xref rid="aoi250039r9" ref-type="bibr">9</xref></sup> stillbirth,<sup><xref rid="aoi250039r1" ref-type="bibr">1</xref>,<xref rid="aoi250039r4" ref-type="bibr">4</xref>,<xref rid="aoi250039r8" ref-type="bibr">8</xref>,<xref rid="aoi250039r9" ref-type="bibr">9</xref></sup> and infant death (death within a year of birth).<sup><xref rid="aoi250039r10" ref-type="bibr">10</xref></sup> For maternal outcomes, cardiac complications,<sup><xref rid="aoi250039r8" ref-type="bibr">8</xref></sup> placental abruption,<sup><xref rid="aoi250039r4" ref-type="bibr">4</xref>,<xref rid="aoi250039r8" ref-type="bibr">8</xref>,<xref rid="aoi250039r9" ref-type="bibr">9</xref></sup> antepartum hemorrhage,<sup><xref rid="aoi250039r7" ref-type="bibr">7</xref></sup> premature rupture of membranes,<sup><xref rid="aoi250039r8" ref-type="bibr">8</xref></sup> infection,<sup><xref rid="aoi250039r4" ref-type="bibr">4</xref></sup> and SMM<sup><xref rid="aoi250039r5" ref-type="bibr">5</xref>,<xref rid="aoi250039r6" ref-type="bibr">6</xref>,<xref rid="aoi250039r7" ref-type="bibr">7</xref></sup> are all associated with opioid use during pregnancy. Previous research has identified several risk factors for SMM, including age extremes,<sup><xref rid="aoi250039r22" ref-type="bibr">22</xref>,<xref rid="aoi250039r23" ref-type="bibr">23</xref>,<xref rid="aoi250039r24" ref-type="bibr">24</xref></sup> body mass index extremes,<sup><xref rid="aoi250039r22" ref-type="bibr">22</xref>,<xref rid="aoi250039r23" ref-type="bibr">23</xref>,<xref rid="aoi250039r24" ref-type="bibr">24</xref></sup> parity extremes,<sup><xref rid="aoi250039r22" ref-type="bibr">22</xref></sup> and medical comorbidities.<sup><xref rid="aoi250039r22" ref-type="bibr">22</xref>,<xref rid="aoi250039r23" ref-type="bibr">23</xref></sup></p></sec><sec id="H2-3-AOI250039"><title>Exposure</title><p>Using filled prescriptions and outpatient administration claims data, we identified evidence of buprenorphine treatment. We assessed for buprenorphine prescriptions between 20 weeks&#8217; EGA and birth using codes provided by the Centers for Disease Control and Prevention (CDC; eTable 2 in <xref rid="note-AOI250039-1-s" ref-type="supplementary-material">Supplement 1</xref>).<sup><xref rid="aoi250039r25" ref-type="bibr">25</xref></sup> Details on our approach to refining the exposure variable are provided in eFigure 2 in <xref rid="note-AOI250039-1-s" ref-type="supplementary-material">Supplement 1</xref>. Buprenorphine was used as the primary medication of choice, as it is the most commonly used in the US, and obtaining detailed data (eg, dose) is possible in prescription claims, whereas these details are not available in claims data for methadone.</p></sec><sec id="H2-4-AOI250039"><title>Outcomes</title><p>Primary maternal outcomes included SMM, ICU admission, and maternal death. The CDC lists 21 diagnoses and procedures that are indicators of SMM.<sup><xref rid="aoi250039r26" ref-type="bibr">26</xref></sup> We compiled the <italic toggle="yes">International Classification of Diseases, Ninth Revision, Clinical Modification</italic> and <italic toggle="yes">International Statistical Classification of Diseases and Related Health Problems, Tenth Revision </italic>codes for the 21 indicators from those published by the CDC and the Alliance for Innovation on Maternal Health (eTable 3 in <xref rid="note-AOI250039-1-s" ref-type="supplementary-material">Supplement 1</xref>). We acquired evidence of ICU admission during the birth hospitalization from the birth certificate. Maternal death was defined as the death of a pregnant person through 6 weeks post partum and was verified with death certificate data.</p><p>Primary infant outcomes included preterm birth (&lt;37 weeks&#8217; gestation), NICU admission, and infant death. We obtained evidence of NICU admission from birth certificates. Infant death was defined as the death of an infant up to 6 weeks post partum and was verified with death certificate data. Secondary infant outcomes from birth certificates included gestational age, birth weight, diagnosis of small for gestational age, and use of assisted ventilation for more than 6 hours. Diagnosis of NOWS was obtained from claims data (eTable 1 in <xref rid="note-AOI250039-1-s" ref-type="supplementary-material">Supplement 1</xref>). We considered NOWS a secondary diagnosis not included in primary models given that it is not an adverse event and can occur from treatment.</p></sec><sec id="H2-5-AOI250039"><title>Covariates</title><p>Covariates were chosen to account for potential factors influencing treatment receipt, which would inform the propensity score. Demographic data for maternal age, race and ethnicity (Hispanic, non-Hispanic Black, non-Hispanic White, and other race [Asian or Pacific Islander and non-Hispanic American Indian or Alaska Native, which were grouped together owing to small sample sizes]), education level, marital status, and location of residence were gathered from birth certificate data. We used Rural-Urban Continuum Codes to categorize zip codes as urban, rural adjacent, and rural remote.<sup><xref rid="aoi250039r27" ref-type="bibr">27</xref></sup> Maternal data acquired from birth certificates included parity, prepregnancy body mass index, chronic medical conditions (prepregnancy diabetes and hypertension), pregnancy-specific medical conditions (gestational hypertension, preeclampsia, and gestational diabetes), infection (hepatitis B/C, syphilis, gonorrhea, and chlamydia), delivery method, history of prior cesarean delivery, early prenatal care (first prenatal visit in first to fourth month of pregnancy), and cigarette smoking during pregnancy. We determined evidence of maternal hepatitis C infection with documentation in either birth certificate or TennCare claims data. Data on maternal substance use disorders (alcohol, amphetamines, cannabis, and cocaine) and maternal mental health diagnoses (depression, anxiety, bipolar disorder, schizophrenia, and other psychotic disorders) were identified using TennCare claims data (eTable 4 in <xref rid="note-AOI250039-1-s" ref-type="supplementary-material">Supplement 1</xref>). For covariates identified using claims data, we identified diagnoses from last menstrual period through delivery.</p></sec><sec id="H2-6-AOI250039"><title>Statistical Analysis</title><p>We compared characteristics of maternal-infant dyads who did and did not receive buprenorphine treatment using medians and IQRs for continuous variables and frequencies and percentages for categorical variables. We tested for differences in cohort characteristics between groups using Wilcoxon rank-sum or &#967;<sup>2</sup> tests. SMM events were stratified by the CDC&#8217;s list of 21 indicators.<sup><xref rid="aoi250039r26" ref-type="bibr">26</xref></sup></p><p>We used propensity score&#8211;weighted logistic regression models to examine the association between buprenorphine treatment and adverse outcomes. The propensity score model included all variables in <xref rid="aoi250039t1" ref-type="table">Table 1</xref> and a categorical variable for birth year. We used the propensity score to calculate overlap weights.<sup><xref rid="aoi250039r28" ref-type="bibr">28</xref></sup> We chose overlap weights instead of inverse probability of treatment weights because overlap weights achieve better covariate balance between treatment groups and handle extreme values better than inverse probability of treatment weights (eFigures 3 and 4 in <xref rid="note-AOI250039-1-s" ref-type="supplementary-material">Supplement 1</xref>).</p><table-wrap position="float" id="aoi250039t1" orientation="portrait"><label>Table 1. </label><caption><title>Characteristics of Pregnant People With Opioid Use Disorder and Their Infants by Receipt of Treatment With Buprenorphine</title></caption><table frame="hsides" rules="groups"><col width="35.47%" span="1"/><col width="26.81%" span="1"/><col width="25.95%" span="1"/><col width="11.77%" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Characteristic</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">No. (%)</th><th rowspan="2" valign="top" align="left" scope="col" colspan="1"><italic toggle="yes">P</italic> value</th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">No buprenorphine treatment (n&#8201;=&#8201;6994)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Buprenorphine treatment (n&#8201;=&#8201;7469)</th></tr></thead><tbody><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">
<bold>Demographics</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Maternal age, median (IQR), y</td><td valign="top" align="left" rowspan="1" colspan="1">27 (24-31)</td><td valign="top" align="left" rowspan="1" colspan="1">27 (24-31)</td><td valign="top" align="left" rowspan="1" colspan="1">.008<xref rid="aoi250039t1n1" ref-type="table-fn"><sup>a</sup></xref></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Maternal race and ethnicity<xref rid="aoi250039t1n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Hispanic</td><td valign="top" align="left" rowspan="1" colspan="1">121 (1.7)</td><td valign="top" align="left" rowspan="1" colspan="1">81 (1.1)</td><td rowspan="4" valign="middle" align="left" colspan="1">&lt;.001<xref rid="aoi250039t1n3" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Non-Hispanic Black</td><td valign="top" align="left" rowspan="1" colspan="1">710 (10.2)</td><td valign="top" align="left" rowspan="1" colspan="1">159 (2.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Non-Hispanic White</td><td valign="top" align="left" rowspan="1" colspan="1">5978 (85.5)</td><td valign="top" align="left" rowspan="1" colspan="1">7075 (94.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Other<xref rid="aoi250039t1n4" ref-type="table-fn"><sup>d</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">185 (2.6)</td><td valign="top" align="left" rowspan="1" colspan="1">154 (2.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Maternal BMI, median (IQR)</td><td valign="top" align="left" rowspan="1" colspan="1">23.3 (20.5-28.1)</td><td valign="top" align="left" rowspan="1" colspan="1">22.7 (20.2-26.6)</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;.001<xref rid="aoi250039t1n1" ref-type="table-fn"><sup>a</sup></xref></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Education</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Less than high school</td><td valign="top" align="left" rowspan="1" colspan="1">84 (1.2)</td><td valign="top" align="left" rowspan="1" colspan="1">83 (1.1)</td><td rowspan="5" valign="middle" align="left" colspan="1">.002<xref rid="aoi250039t1n3" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> High school</td><td valign="top" align="left" rowspan="1" colspan="1">4846 (69.6)</td><td valign="top" align="left" rowspan="1" colspan="1">5058 (68.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Some college credit</td><td valign="top" align="left" rowspan="1" colspan="1">1655 (23.8)</td><td valign="top" align="left" rowspan="1" colspan="1">1958 (26.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> College degree</td><td valign="top" align="left" rowspan="1" colspan="1">359 (5.2)</td><td valign="top" align="left" rowspan="1" colspan="1">325 (4.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Graduate school and higher</td><td valign="top" align="left" rowspan="1" colspan="1">18 (0.3)</td><td valign="top" align="left" rowspan="1" colspan="1">12 (0.2)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Rurality<xref rid="aoi250039t1n2" ref-type="table-fn"><sup>b</sup></xref><sup>,</sup><xref rid="aoi250039t1n5" ref-type="table-fn"><sup>e</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Rural adjacent</td><td valign="top" align="left" rowspan="1" colspan="1">1755 (25.1)</td><td valign="top" align="left" rowspan="1" colspan="1">1766 (23.6)</td><td rowspan="3" valign="middle" align="left" colspan="1">&lt;.001<xref rid="aoi250039t1n3" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Rural remote</td><td valign="top" align="left" rowspan="1" colspan="1">388 (5.5)</td><td valign="top" align="left" rowspan="1" colspan="1">325 (4.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Urban</td><td valign="top" align="left" rowspan="1" colspan="1">4850 (69.4)</td><td valign="top" align="left" rowspan="1" colspan="1">5378 (72.0)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">
<bold>Pregnancy-specific characteristics</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">No. of previous births, median (IQR)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (1-2)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (1-2)</td><td valign="top" align="left" rowspan="1" colspan="1">.02<xref rid="aoi250039t1n1" ref-type="table-fn"><sup>a</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Previous cesarean delivery<xref rid="aoi250039t1n6" ref-type="table-fn"><sup>f</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">1352 (19.3)</td><td valign="top" align="left" rowspan="1" colspan="1">1466 (19.6)</td><td valign="top" align="left" rowspan="1" colspan="1">.67<xref rid="aoi250039t1n3" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Early prenatal care<xref rid="aoi250039t1n6" ref-type="table-fn"><sup>f</sup></xref><sup>,</sup><xref rid="aoi250039t1n7" ref-type="table-fn"><sup>g</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">4376 (68.5)</td><td valign="top" align="left" rowspan="1" colspan="1">4702 (69.1)</td><td valign="top" align="left" rowspan="1" colspan="1">.46<xref rid="aoi250039t1n3" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Prepregnancy diabetes<xref rid="aoi250039t1n6" ref-type="table-fn"><sup>f</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">95 (1.4)</td><td valign="top" align="left" rowspan="1" colspan="1">68 (0.9)</td><td valign="top" align="left" rowspan="1" colspan="1">.01<xref rid="aoi250039t1n3" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Gestational diabetes<xref rid="aoi250039t1n6" ref-type="table-fn"><sup>f</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">441 (6.3)</td><td valign="top" align="left" rowspan="1" colspan="1">331 (4.4)</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;.001<xref rid="aoi250039t1n3" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Prepregnancy hypertension<xref rid="aoi250039t1n6" ref-type="table-fn"><sup>f</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">289 (4.1)</td><td valign="top" align="left" rowspan="1" colspan="1">260 (3.5)</td><td valign="top" align="left" rowspan="1" colspan="1">.045<xref rid="aoi250039t1n3" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Gestational hypertension/preeclampsia<xref rid="aoi250039t1n6" ref-type="table-fn"><sup>f</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">401 (5.7)</td><td valign="top" align="left" rowspan="1" colspan="1">270 (3.6)</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;.001<xref rid="aoi250039t1n3" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Maternal mental health diagnoses<xref rid="aoi250039t1n6" ref-type="table-fn"><sup>f</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2508 (35.9)</td><td valign="top" align="left" rowspan="1" colspan="1">2791 (37.4)</td><td valign="top" align="left" rowspan="1" colspan="1">.06<xref rid="aoi250039t1n3" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">
<bold>Maternal infections</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Hepatitis B<xref rid="aoi250039t1n6" ref-type="table-fn"><sup>f</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">47 (0.7)</td><td valign="top" align="left" rowspan="1" colspan="1">74 (1.0)</td><td valign="top" align="left" rowspan="1" colspan="1">.04<xref rid="aoi250039t1n3" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Hepatitis C<xref rid="aoi250039t1n6" ref-type="table-fn"><sup>f</sup></xref><sup>,</sup><xref rid="aoi250039t1n8" ref-type="table-fn"><sup>h</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">988 (14.1)</td><td valign="top" align="left" rowspan="1" colspan="1">1687 (22.6)</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;.001<xref rid="aoi250039t1n3" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Gonorrhea<xref rid="aoi250039t1n6" ref-type="table-fn"><sup>f</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">67 (1.0)</td><td valign="top" align="left" rowspan="1" colspan="1">58 (0.8)</td><td valign="top" align="left" rowspan="1" colspan="1">.28<xref rid="aoi250039t1n3" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Chlamydia<xref rid="aoi250039t1n6" ref-type="table-fn"><sup>f</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">323 (4.6)</td><td valign="top" align="left" rowspan="1" colspan="1">271 (3.6)</td><td valign="top" align="left" rowspan="1" colspan="1">.003<xref rid="aoi250039t1n3" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Syphilis<xref rid="aoi250039t1n6" ref-type="table-fn"><sup>f</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">23 (0.3)</td><td valign="top" align="left" rowspan="1" colspan="1">16 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1">.24<xref rid="aoi250039t1n3" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">
<bold>Substance use</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Smoking<xref rid="aoi250039t1n6" ref-type="table-fn"><sup>f</sup></xref><sup>,</sup><xref rid="aoi250039t1n9" ref-type="table-fn"><sup>i</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">4482 (64.8)</td><td valign="top" align="left" rowspan="1" colspan="1">5511 (74.4)</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;.001<xref rid="aoi250039t1n3" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Alcohol use disorder and drug use complicating pregnancy<xref rid="aoi250039t1n6" ref-type="table-fn"><sup>f</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">3080 (44.0)</td><td valign="top" align="left" rowspan="1" colspan="1">3999 (53.5)</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;.001<xref rid="aoi250039t1n3" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Amphetamine use disorder<xref rid="aoi250039t1n6" ref-type="table-fn"><sup>f</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">545 (7.8)</td><td valign="top" align="left" rowspan="1" colspan="1">476 (6.4)</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;.001<xref rid="aoi250039t1n3" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Cannabis use disorder<xref rid="aoi250039t1n6" ref-type="table-fn"><sup>f</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">706 (10.1)</td><td valign="top" align="left" rowspan="1" colspan="1">546 (7.3)</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;.001<xref rid="aoi250039t1n3" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Cocaine use disorder<xref rid="aoi250039t1n6" ref-type="table-fn"><sup>f</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">268 (3.8)</td><td valign="top" align="left" rowspan="1" colspan="1">185 (2.5)</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;.001<xref rid="aoi250039t1n3" ref-type="table-fn"><sup>c</sup></xref></td></tr></tbody></table><table-wrap-foot><p>Abbreviation: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared).</p><fn id="aoi250039t1n1"><label>
<sup>a</sup>
</label><p>Wilcoxon rank-sum test.</p></fn><fn id="aoi250039t1n2"><label>
<sup>b</sup>
</label><p>Percentages may not sum to 100% due to missingness.</p></fn><fn id="aoi250039t1n3"><label>
<sup>c</sup>
</label><p>Pearson &#967;<sup>2</sup> test.</p></fn><fn id="aoi250039t1n4"><label>
<sup>d</sup>
</label><p>This category includes Asian or Pacific Islander and non-Hispanic American Indian or Alaska Native. These races were reported together owing to small sample sizes.</p></fn><fn id="aoi250039t1n5"><label>
<sup>e</sup>
</label><p>Defined using Rural-Urban Continuum Codes.</p></fn><fn id="aoi250039t1n6"><label>
<sup>f</sup>
</label><p>Reported for those responding yes.</p></fn><fn id="aoi250039t1n7"><label>
<sup>g</sup>
</label><p>Defined as evidence of first prenatal visit in the first to fourth month of pregnancy.</p></fn><fn id="aoi250039t1n8"><label>
<sup>h</sup>
</label><p>Defined as evidence of hepatitis C infection in both birth certificate and claims data.</p></fn><fn id="aoi250039t1n9"><label>
<sup>i</sup>
</label><p>Defined as evidence of smoking in the first trimester.</p></fn></table-wrap-foot></table-wrap><p>We created separate weighted logistic regression models for 1 maternal outcome (SMM), 2 infant outcomes (preterm birth and NICU admission), and 3 composite outcomes (any adverse outcome for the mother, any adverse outcome for the infant, and any adverse outcome for the mother or infant). We calculated odds ratios (ORs) from the logistic regression models, then we calculated the predicted probabilities of adverse outcomes in the buprenorphine-treated and untreated groups by applying these models, varying only if buprenorphine was used.</p><p>As additional analyses, we first examined the association of days&#8217; supply of buprenorphine and the average daily dose among individuals prescribed buprenorphine with the risk of adverse outcomes. Next, we examined the timing of buprenorphine treatment by comparing 2 groups to determine if chronic use in the month before delivery modified outcomes: (1) those who had at least 14 days of buprenorphine use in the 30 days predelivery and (2) those with no buprenorphine use during the same 30-day period. Weighted logistic regression models were used in supplemental analyses similar to those previously described for the primary analysis. Restricted cubic splines were applied to nonlinear covariates (eg, days&#8217; supply). We used a weighted negative binomial model to compare the length of birth hospitalization as the outcome between the treated and untreated groups. To test the robustness of these findings to the continuous enrollment requirement, we conducted a sensitivity analysis restricted to the cohort continuously enrolled in TennCare from 90 days prior to birth to 6 weeks post partum. Lastly, we conducted the primary analysis limited only to those with a diagnosis of OUD.</p><p>All analyses were conducted using R, version 4.2.1 (R Foundation for Statistical Computing). The PSweight package was used to calculate propensity scores. <italic toggle="yes">P</italic> values were 2-sided, with <italic toggle="yes">P</italic>&#8201;&lt;&#8201;.05 representing statistical significance. Analyses were conducted from April to October 2024.</p></sec></sec><sec id="H1-3-AOI250039"><title>Results</title><sec id="H2-7-AOI250039"><title>Cohort Characteristics</title><p>From 2010 to 2021, 14&#8201;463 maternal-infant dyads met the inclusion criteria, including 7469 dyads (51.6%) who received buprenorphine (median [IQR] maternal age, 27 [24-31] years). Among pregnant people treated with buprenorphine, 81 (1.1%) identified as Hispanic, 159 (2.1%) as non-Hispanic Black (hereafter Black), 7075 (94.7%) as non-Hispanic White (hereafter White), and 154 (2.1%) as another race. In contrast, in the untreated group, 212 (1.7%) identified as Hispanic, 710 (10.2%) as Black, 5978 (85.5%) as White, and 185 (2.6%) as another race (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;.001). Other demographic and pregnancy-specific characteristics were similar between both treated and untreated groups in the cohort, including lack of early prenatal care (2767 [30.9%] vs 2618 [31.5%]; <italic toggle="yes">P</italic>&#8201;=&#8201;.46) and attainment of high school degree or less (2328 [69.1%] vs 2064 [70.8%]; <italic toggle="yes">P</italic>&#8201;=&#8201;.002). The presence of comorbid substance use, such as smoking (5511 [74.4%] vs 4482 [64.8%]; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;.001) was also high in both the treated and untreated groups (<xref rid="aoi250039t1" ref-type="table">Table 1</xref> and eTables 5 and 6 in <xref rid="note-AOI250039-1-s" ref-type="supplementary-material">Supplement 1</xref>).</p></sec><sec id="H2-8-AOI250039"><title>Trends in Adverse Pregnancy Outcomes</title><p>The yearly rate of adverse pregnancy outcomes in the cohort increased from 27.0% to 31.6%. While the rate of adverse maternal outcomes (SMM, ICU admission, and maternal death) increased from 4.9% to 5.6%, the rate of adverse infant outcomes (preterm birth, NICU admission, and infant death) increased from 24.5% to 29.7% (<xref rid="aoi250039f1" ref-type="fig">Figure</xref> and eFigures 5 and 6 in <xref rid="note-AOI250039-1-s" ref-type="supplementary-material">Supplement 1</xref>).</p><fig position="float" id="aoi250039f1" fig-type="figure" orientation="portrait"><label>Figure. </label><caption><title>Adverse Pregnancy Outcomes Among Pregnant People With Opioid Use Disorder in Tennessee, 2010-2021</title><p>Adverse maternal outcomes include severe maternal morbidity, intensive care unit admission, and maternal death. Adverse infant outcomes include preterm birth, neonatal intensive care unit admission, and infant death. Adverse maternal-infant dyad outcomes include any reported outcome. The shaded areas indicate 95% CIs.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jamahealthforum-e251814-g001.jpg"/></fig><p>Overall, between the treated and untreated groups, there was a statistically significant lower rate of adverse pregnancy outcomes in those treated with buprenorphine compared to those who were untreated (25.4% vs 30.8%; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;.001). Specifically, the buprenorphine treatment group had a lower rate of SMM events (5.4% vs 6.9%; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;.001), preterm births (14.1% vs 20.0%; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;.001), and NICU admissions (15.2% vs 17.2%; <italic toggle="yes">P</italic>&#8201;=&#8201;.001). The rate of infants with NOWS diagnoses was higher in the treated vs the untreated group (51.7% vs 32.4%; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;.001). There was no statistically significant difference in the rates of ICU admission, maternal death, or infant death (<xref rid="aoi250039t2" ref-type="table">Table 2</xref> and eTable 7 in <xref rid="note-AOI250039-1-s" ref-type="supplementary-material">Supplement 1</xref>). Among individual SMM indicators, there was a lower rate of blood transfusions (1.8% vs 2.4%; <italic toggle="yes">P</italic>&#8201;=&#8201;.006), hysterectomies (0.1% vs 0.3%; <italic toggle="yes">P</italic>&#8201;=&#8201;.01), and pulmonary edema/acute heart failure events (0.4% vs 0.8%; <italic toggle="yes">P</italic>&#8201;=&#8201;.009) between pregnant people treated with buprenorphine and those without treatment (<xref rid="aoi250039t3" ref-type="table">Table 3</xref> and eTable 8 in <xref rid="note-AOI250039-1-s" ref-type="supplementary-material">Supplement 1</xref>).</p><table-wrap position="float" id="aoi250039t2" orientation="portrait"><label>Table 2. </label><caption><title>Unadjusted Adverse Pregnancy Outcomes by Receipt of Medications for Opioid Use Disorder From 20 Weeks&#8217; Gestation to 6 Weeks Post Partum</title></caption><table frame="hsides" rules="groups"><col width="38.23%" span="1"/><col width="23.54%" span="1"/><col width="24.53%" span="1"/><col width="13.7%" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Outcome</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">No. (%)</th><th rowspan="2" valign="top" align="left" scope="col" colspan="1"><italic toggle="yes">P</italic> value<xref rid="aoi250039t2n1" ref-type="table-fn"><sup>a</sup></xref></th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">No buprenorphine treatment (n&#8201;=&#8201;6994)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Buprenorphine treatment (n&#8201;=&#8201;7469)</th></tr></thead><tbody><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Primary maternal outcomes</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Severe maternal morbidity</td><td valign="top" align="left" rowspan="1" colspan="1">483 (6.9)</td><td valign="top" align="left" rowspan="1" colspan="1">403 (5.4)</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Intensive care unit admission</td><td valign="top" align="left" rowspan="1" colspan="1">34 (0.5)</td><td valign="top" align="left" rowspan="1" colspan="1">25 (0.3)</td><td valign="top" align="left" rowspan="1" colspan="1">.19</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Maternal death</td><td valign="top" align="left" rowspan="1" colspan="1">NR (&lt;0.1)<xref rid="aoi250039t2n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">NR (0)<xref rid="aoi250039t2n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">.12</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Primary infant outcomes</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Preterm birth (gestational age &lt;37 wk)</td><td valign="top" align="left" rowspan="1" colspan="1">1392 (20.0)</td><td valign="top" align="left" rowspan="1" colspan="1">1055 (14.0)</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Neonatal intensive care unit admission</td><td valign="top" align="left" rowspan="1" colspan="1">1204 (17.2)</td><td valign="top" align="left" rowspan="1" colspan="1">1135 (15.2)</td><td valign="top" align="left" rowspan="1" colspan="1">.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Infant death</td><td valign="top" align="left" rowspan="1" colspan="1">NR (0.1)<xref rid="aoi250039t2n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">14 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1">.50</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Secondary infant outcomes</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Gestational age, median (IQR), wk</td><td valign="top" align="left" rowspan="1" colspan="1">38 (37-39)</td><td valign="top" align="left" rowspan="1" colspan="1">39 (37-39)</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Neonatal opioid withdrawal syndrome</td><td valign="top" align="left" rowspan="1" colspan="1">2263 (32.4)</td><td valign="top" align="left" rowspan="1" colspan="1">3859 (51.7)</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Birth weight, median (IQR), g</td><td valign="top" align="left" rowspan="1" colspan="1">2985 (2590-3330)</td><td valign="top" align="left" rowspan="1" colspan="1">2995 (2640-3317)</td><td valign="top" align="left" rowspan="1" colspan="1">.29</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Small for gestational age</td><td valign="top" align="left" rowspan="1" colspan="1">1517 (21.9)</td><td valign="top" align="left" rowspan="1" colspan="1">1854 (24.9)</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Assisted ventilation required for &gt;6 h</td><td valign="top" align="left" rowspan="1" colspan="1">236 (3.4)</td><td valign="top" align="left" rowspan="1" colspan="1">257 (3.4)</td><td valign="top" align="left" rowspan="1" colspan="1">.86</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Any primary adverse pregnancy outcome</td><td valign="top" align="left" rowspan="1" colspan="1">2157 (30.8)</td><td valign="top" align="left" rowspan="1" colspan="1">1899 (25.4)</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td></tr></tbody></table><table-wrap-foot><p>Abbreviation: NR, not reported.</p><fn id="aoi250039t2n1"><label>
<sup>a</sup>
</label><p>Pearson &#967;<sup>2</sup> test.</p></fn><fn id="aoi250039t2n2"><label>
<sup>b</sup>
</label><p>Samples fewer than 10 have been suppressed.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="aoi250039t3" orientation="portrait"><label>Table 3. </label><caption><title>Severe Maternal Morbidity Indicators Among Pregnant People by Receipt of Medication for Opioid Use Disorder</title></caption><table frame="hsides" rules="groups"><col width="44.69%" span="1"/><col width="22.8%" span="1"/><col width="21.92%" span="1"/><col width="10.59%" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Severe maternal morbidity category</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">No. (%)</th><th rowspan="2" valign="top" align="left" scope="col" colspan="1"><italic toggle="yes">P</italic> value<xref rid="aoi250039t3n1" ref-type="table-fn"><sup>a</sup></xref></th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">No buprenorphine treatment (n&#8201;=&#8201;6994)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Buprenorphine treatment (n&#8201;=&#8201;7469)</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Puerperal cerebrovascular disorders</td><td valign="top" align="left" rowspan="1" colspan="1">24 (0.3)</td><td valign="top" align="left" rowspan="1" colspan="1">28 (0.4)</td><td valign="top" align="left" rowspan="1" colspan="1">.86</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Cardiac</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Acute myocardial infarction</td><td valign="top" align="left" rowspan="1" colspan="1">NR (&lt;0.1)<xref rid="aoi250039t3n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">NR (&lt;0.1)<xref rid="aoi250039t3n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">&gt;.99</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Aneurysm</td><td valign="top" align="left" rowspan="1" colspan="1">NR (&lt;0.1)<xref rid="aoi250039t3n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">NR (&lt;0.1)<xref rid="aoi250039t3n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">&gt;.99</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Cardiac arrest/ventricular fibrillation</td><td valign="top" align="left" rowspan="1" colspan="1">NR (&lt;0.1)<xref rid="aoi250039t3n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">NR (&lt;0.1)<xref rid="aoi250039t3n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">.44</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Pulmonary edema/acute heart failure</td><td valign="top" align="left" rowspan="1" colspan="1">53 (0.8)</td><td valign="top" align="left" rowspan="1" colspan="1">31 (0.4)</td><td valign="top" align="left" rowspan="1" colspan="1">.009</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Acute respiratory distress syndrome</td><td valign="top" align="left" rowspan="1" colspan="1">81 (1.2)</td><td valign="top" align="left" rowspan="1" colspan="1">75 (1.0)</td><td valign="top" align="left" rowspan="1" colspan="1">.42</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Acute kidney failure</td><td valign="top" align="left" rowspan="1" colspan="1">28 (0.4)</td><td valign="top" align="left" rowspan="1" colspan="1">18 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1">.12</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Vascular</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Air and thrombotic embolism</td><td valign="top" align="left" rowspan="1" colspan="1">28 (0.4)</td><td valign="top" align="left" rowspan="1" colspan="1">19 (0.3)</td><td valign="top" align="left" rowspan="1" colspan="1">.16</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Eclampsia</td><td valign="top" align="left" rowspan="1" colspan="1">37 (0.5)</td><td valign="top" align="left" rowspan="1" colspan="1">25 (0.3)</td><td valign="top" align="left" rowspan="1" colspan="1">.10</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Sickle cell disease with crisis</td><td valign="top" align="left" rowspan="1" colspan="1">NR (0.1)<xref rid="aoi250039t3n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">NR (0)<xref rid="aoi250039t3n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">.006</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Circulatory</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Amniotic fluid embolism</td><td valign="top" align="left" rowspan="1" colspan="1">NR (&lt;0.1)<xref rid="aoi250039t3n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">NR (&lt;0.1)<xref rid="aoi250039t3n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">.66</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Disseminated intravascular coagulation</td><td valign="top" align="left" rowspan="1" colspan="1">63 (0.9)</td><td valign="top" align="left" rowspan="1" colspan="1">60 (0.8)</td><td valign="top" align="left" rowspan="1" colspan="1">.58</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Sepsis</td><td valign="top" align="left" rowspan="1" colspan="1">87 (1.2)</td><td valign="top" align="left" rowspan="1" colspan="1">76 (1.0)</td><td valign="top" align="left" rowspan="1" colspan="1">.23</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Shock</td><td valign="top" align="left" rowspan="1" colspan="1">10 (0.1)</td><td valign="top" align="left" rowspan="1" colspan="1">15 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1">.52</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Procedures</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Blood transfusion</td><td valign="top" align="left" rowspan="1" colspan="1">169 (2.4)</td><td valign="top" align="left" rowspan="1" colspan="1">131 (1.8)</td><td valign="top" align="left" rowspan="1" colspan="1">.006</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Conversion of cardiac rhythm</td><td valign="top" align="left" rowspan="1" colspan="1">NR (&lt;0.1)<xref rid="aoi250039t3n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">NR (&lt;0.1)<xref rid="aoi250039t3n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">&gt;.99</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Hysterectomy</td><td valign="top" align="left" rowspan="1" colspan="1">22 (0.3)</td><td valign="top" align="left" rowspan="1" colspan="1">NR (0.1)<xref rid="aoi250039t3n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">.01</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Temporary tracheostomy</td><td valign="top" align="left" rowspan="1" colspan="1">NR (&lt;0.1)<xref rid="aoi250039t3n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">NR (&lt;0.1)<xref rid="aoi250039t3n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">.96</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Ventilation</td><td valign="top" align="left" rowspan="1" colspan="1">63 (0.9)</td><td valign="top" align="left" rowspan="1" colspan="1">49 (0.7)</td><td valign="top" align="left" rowspan="1" colspan="1">.11</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Procedural complications</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Heart failure/arrest during surgery or procedure</td><td valign="top" align="left" rowspan="1" colspan="1">NR (0)<xref rid="aoi250039t3n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">NR (0)<xref rid="aoi250039t3n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">NA</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Severe anesthesia complications</td><td valign="top" align="left" rowspan="1" colspan="1">NR (&lt;0.1)<xref rid="aoi250039t3n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">NR (&lt;0.1)<xref rid="aoi250039t3n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">&gt;.99</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: NA, not applicable; NR, not reported.</p><fn id="aoi250039t3n1"><label>
<sup>a</sup>
</label><p>Pearson &#967;<sup>2</sup> test.</p></fn><fn id="aoi250039t3n2"><label>
<sup>b</sup>
</label><p>Samples fewer than 10 have been suppressed.</p></fn></table-wrap-foot></table-wrap></sec><sec id="H2-9-AOI250039"><title>Buprenorphine Treatment and Adjusted Probability of Adverse Pregnancy Outcomes</title><p>In the logistic regression model with propensity score overlap weighting to account for differences between treatment groups, buprenorphine treatment was associated with a lower likelihood of composite adverse pregnancy outcomes (OR, 0.77; 95% CI, 0.70-0.83), with predicted probabilities of adverse pregnancy outcomes being 23.0% (95% CI, 22.0%-24.1%) in treated individuals compared to 28.1% (95% CI, 26.9%-29.3%) among those not treated. The number needed to treat (NNT) to prevent 1 adverse outcome was 20.</p><p>Odds of SMM were lower for those treated with buprenorphine (OR, 0.80; 95% CI, 0.68-0.93), with predicted probabilities of 5.0% (95% CI, 4.5%-5.6%) for those treated compared to 6.2% (95% CI, 5.6%-6.9%) for no treatment (NNT, 83). Infants born to treated mothers were less likely to be born preterm (OR, 0.65; 95% CI, 0.58-0.72), with predicted probabilities of preterm birth being 11.7% (95% CI, 10.8%-12.5%) in the treated group compared to 17.0% (95% CI, 16.0%-18.0%) in the untreated group (NNT, 19) (<xref rid="aoi250039t4" ref-type="table">Table 4</xref> and eFigure 7 in <xref rid="note-AOI250039-1-s" ref-type="supplementary-material">Supplement 1</xref>).</p><table-wrap position="float" id="aoi250039t4" orientation="portrait"><label>Table 4. </label><caption><title>Association of Buprenorphine Treatment With Adverse Pregnancy Outcomes Among Pregnant People With Opioid Use Disorder After Applying Propensity Scores With Overlap Weights<xref rid="aoi250039t4n1" ref-type="table-fn"><sup>a</sup></xref></title></caption><table frame="hsides" rules="groups"><col width="33.33%" span="1"/><col width="28.15%" span="1"/><col width="11.34%" span="1"/><col width="27.18%" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Outcome</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">OR (95% CI)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Predicted probability, % (95% CI)</th></tr></thead><tbody><tr><td colspan="4" valign="top" align="left" scope="col" rowspan="1">
<bold>Adverse pregnancy outcome (mother or infant)<xref rid="aoi250039t4n2" ref-type="table-fn"><sup>b</sup></xref></bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">No buprenorphine exposure</td><td valign="top" align="left" rowspan="1" colspan="1">1 [Reference]</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">28.1 (26.9-29.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Buprenorphine exposure</td><td valign="top" align="left" rowspan="1" colspan="1">0.77 (0.70-0.83)</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td><td valign="top" align="left" rowspan="1" colspan="1">23.0 (22.0-24.1)</td></tr><tr><td colspan="4" valign="top" align="left" scope="col" rowspan="1">
<bold>Adverse pregnancy outcome for the mother<xref rid="aoi250039t4n3" ref-type="table-fn"><sup>c</sup></xref></bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">No buprenorphine exposure</td><td valign="top" align="left" rowspan="1" colspan="1">1 [Reference]</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">6.3 (5.7-6.9)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Buprenorphine exposure</td><td valign="top" align="left" rowspan="1" colspan="1">0.80 (0.68-0.93)</td><td valign="top" align="left" rowspan="1" colspan="1">.005</td><td valign="top" align="left" rowspan="1" colspan="1">5.1 (4.5-5.6)</td></tr><tr><td colspan="4" valign="top" align="left" scope="col" rowspan="1">
<bold>Severe maternal morbidity</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">No buprenorphine exposure</td><td valign="top" align="left" rowspan="1" colspan="1">1 [Reference]</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">6.2 (5.6-6.9)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Buprenorphine exposure</td><td valign="top" align="left" rowspan="1" colspan="1">0.80 (0.68-0.93)</td><td valign="top" align="left" rowspan="1" colspan="1">.005</td><td valign="top" align="left" rowspan="1" colspan="1">5.0 (4.5-5.6)</td></tr><tr><td colspan="4" valign="top" align="left" scope="col" rowspan="1">
<bold>Adverse outcome for the infant<xref rid="aoi250039t4n4" ref-type="table-fn"><sup>d</sup></xref></bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">No buprenorphine exposure</td><td valign="top" align="left" rowspan="1" colspan="1">1 [Reference]</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">25.0 (23.9-26.2)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Buprenorphine exposure</td><td valign="top" align="left" rowspan="1" colspan="1">0.76 (0.70-0.83)</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td><td valign="top" align="left" rowspan="1" colspan="1">20.3 (19.2-21.3)</td></tr><tr><td colspan="4" valign="top" align="left" scope="col" rowspan="1">
<bold>Preterm birth</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">No buprenorphine exposure</td><td valign="top" align="left" rowspan="1" colspan="1">1 [Reference]</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">17.0 (16.0-18.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Buprenorphine exposure</td><td valign="top" align="left" rowspan="1" colspan="1">0.65 (0.58-0.72)</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td><td valign="top" align="left" rowspan="1" colspan="1">11.7 (10.8-12.5)</td></tr><tr><td colspan="4" valign="top" align="left" scope="col" rowspan="1">
<bold>NICU admission</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">No buprenorphine exposure</td><td valign="top" align="left" rowspan="1" colspan="1">1 [Reference]</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">15.5 (14.5-16.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Buprenorphine exposure</td><td valign="top" align="left" rowspan="1" colspan="1">0.88 (0.79-0.97)</td><td valign="top" align="left" rowspan="1" colspan="1">.01</td><td valign="top" align="left" rowspan="1" colspan="1">13.8 (12.9-14.7)</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: NA, not applicable; NICU, neonatal intensive care unit; OR, odds ratio.</p><fn id="aoi250039t4n1"><label>
<sup>a</sup>
</label><p>Percentages were obtained by using propensity score&#8211;weighted logistic regression models to calculate predicted probabilities and multiplying them by 100. ORs were calculated as (P<sub>1</sub>/[1&#8201;&#8722;&#8201;P<sub>1</sub>])/(P<sub>0</sub>/[1&#8201;&#8722;&#8201;P<sub>0</sub>]), where P<sub>1</sub> is the predicted probability in the buprenorphine exposure group and P<sub>0</sub> is the predicted probability in the no buprenorphine exposure group.</p></fn><fn id="aoi250039t4n2"><label>
<sup>b</sup>
</label><p>Includes any severe maternal morbidity indicator, intensive care unit admission, maternal death, preterm birth, NICU admission, or infant death.</p></fn><fn id="aoi250039t4n3"><label>
<sup>c</sup>
</label><p>Includes any severe maternal morbidity indicator, intensive care unit admission, or maternal death.</p></fn><fn id="aoi250039t4n4"><label>
<sup>d</sup>
</label><p>Includes preterm birth, NICU admission, or infant death.</p></fn></table-wrap-foot></table-wrap><p>These findings were also similar in supplementary analyses (eFigures 8-17 and eTables 9-16 in <xref rid="note-AOI250039-1-s" ref-type="supplementary-material">Supplement 1</xref>). In the supplementary analyses, among pregnant people treated with buprenorphine, timing, days treated, or dose did not change the associations with treatment receipt and pregnancy outcomes, nor did limiting to only those with an OUD diagnosis in pregnancy.</p></sec></sec><sec id="H1-4-AOI250039"><title>Discussion</title><p>In this study of maternal-infant dyads with maternal OUD, we found that treatment with buprenorphine for OUD during pregnancy was associated with a lower probability of adverse pregnancy outcomes for pregnant individuals and their infants compared to those without treatment (OR, 0.77; 95% CI, 0.70-0.83). Buprenorphine treatment was associated with a 1.2 percentage point (pp; 95% CI, 0.4-2.1 pp) lower risk of experiencing a maternal SMM event and a 5.3 pp (95% CI, 4.0-6.6 pp) lower risk of preterm birth for infants. We did not find that dose was associated with changes in these outcomes, which might reflect a ceiling effect, and that once women began taking buprenorphine, most continued it.</p><p>The rate of SMM has increased 45% in the US over the past 20 years.<sup><xref rid="aoi250039r5" ref-type="bibr">5</xref></sup> The risk of SMM is elevated for pregnant individuals with OUD<sup><xref rid="aoi250039r5" ref-type="bibr">5</xref>,<xref rid="aoi250039r6" ref-type="bibr">6</xref>,<xref rid="aoi250039r7" ref-type="bibr">7</xref></sup> and is often viewed as a near miss of maternal death&#8212;for every maternal death, there are an estimated 100 SMM events.<sup><xref rid="aoi250039r29" ref-type="bibr">29</xref></sup> SMM not only poses a substantial risk to the health of the mother, but is also associated with adverse outcomes for the infant, including NICU admission, stillbirth, preterm birth, and low birth weight.<sup><xref rid="aoi250039r30" ref-type="bibr">30</xref></sup> Although SMM rates have continued to trend upward in the US, these events are considered largely preventable.<sup><xref rid="aoi250039r29" ref-type="bibr">29</xref></sup> Previous studies of pregnant people with OUD treated with buprenorphine vs methadone found no statistically significant difference in maternal outcomes between treatment groups<sup><xref rid="aoi250039r17" ref-type="bibr">17</xref>,<xref rid="aoi250039r18" ref-type="bibr">18</xref></sup>; however, there are limited data examining whether buprenorphine treatment vs no treatment modifies the risk of SMM specifically. We found that treatment with buprenorphine was associated with reduced risks of SMM among pregnant people with OUD.</p><p>Preterm birth is a growing public health issue in the US, complicating 10.4% of all pregnancies as of 2022.<sup><xref rid="aoi250039r31" ref-type="bibr">31</xref></sup> Prior studies have demonstrated an association between OUD during pregnancy and preterm birth,<sup><xref rid="aoi250039r1" ref-type="bibr">1</xref>,<xref rid="aoi250039r4" ref-type="bibr">4</xref>,<xref rid="aoi250039r7" ref-type="bibr">7</xref>,<xref rid="aoi250039r8" ref-type="bibr">8</xref>,<xref rid="aoi250039r9" ref-type="bibr">9</xref></sup> with some reporting rates of preterm birth as high as 20% in pregnant people with OUD.<sup><xref rid="aoi250039r19" ref-type="bibr">19</xref></sup> Similar to these reports, we found that rates of preterm birth among maternal-infant dyads with OUD were higher than the national average (eFigures 5 and 6 in <xref rid="note-AOI250039-1-s" ref-type="supplementary-material">Supplement 1</xref>). While previous research has shown a lower preterm birth rate among individuals treated with buprenorphine compared to methadone, there are limited data rigorously evaluating if buprenorphine treatment reduces preterm birth compared to no treatment.<sup><xref rid="aoi250039r18" ref-type="bibr">18</xref></sup> This study demonstrates a statistically significant decrease in probability of preterm birth with buprenorphine treatment during pregnancy compared to no treatment.</p><p>Although characteristics were largely similar between the treated and untreated dyads in this study, we found that pregnant people who received buprenorphine treatment for OUD were less likely to be Black (10.2% vs 2.1%), similar to other studies.<sup><xref rid="aoi250039r32" ref-type="bibr">32</xref>,<xref rid="aoi250039r33" ref-type="bibr">33</xref></sup> A recent US Department of Health and Human Services report found that only 18% of Black women received medication for OUD during pregnancy compared to 48% of White women, highlighting the stark need for equitable treatment access.<sup><xref rid="aoi250039r34" ref-type="bibr">34</xref></sup> While provisional CDC data reported a national decrease in overdose,<sup><xref rid="aoi250039r35" ref-type="bibr">35</xref></sup> some states have reported increases, especially among individuals who identify as Black.<sup><xref rid="aoi250039r36" ref-type="bibr">36</xref></sup> For example, in Tennessee, substance use played a role in more than 1 in 4 pregnancy-associated deaths from 2017 to 2020; Black individuals were 2.5 times more likely than White counterparts to die during or in the year following pregnancy.<sup><xref rid="aoi250039r37" ref-type="bibr">37</xref></sup> The present study highlights the importance of closing the racial gap in treatment receipt during pregnancy.</p><p>Treatment of OUD in pregnancy remains challenging in the US. A recent secret-shopper study found that pregnant women were 17 percentage points less likely to be accepted as identical nonpregnant women.<sup><xref rid="aoi250039r38" ref-type="bibr">38</xref></sup> Moreover, it is unclear whether state laws prioritizing pregnant individuals for treatment have been effective at improving access.<sup><xref rid="aoi250039r39" ref-type="bibr">39</xref></sup> We find that treatment may improve pregnancy outcomes for both the pregnant individual and the infant, with the most considerable benefit being the reduction of preterm births. These findings, coupled with rising rates of overdose rates in pregnancy, provide additional evidence to support treatment expansion for pregnant individuals.<sup><xref rid="aoi250039r40" ref-type="bibr">40</xref></sup></p><sec id="H2-10-AOI250039"><title>Limitations</title><p>This study has several limitations that merit mentioning. First, residual confounding is possible despite our use of multiple data sources and propensity scores with overlap weighting. Second, misclassification bias, including errors of omission or commission, is possible in the primary data sources. Third, we used filled prescription records for buprenorphine but did not observe actual medication administration, which may bias the results. Fourth, though this study focused on a large population-based cohort of Medicaid enrollees in Tennessee (representing approximately 50% of all Tennessee births), it may not be generalizable beyond Tennessee or to non-Medicaid populations. Fifth, it is possible that diagnoses, including mental health diagnoses, occurred before pregnancy and were not detected during the study period, which could have confounded the results.</p></sec></sec><sec id="H1-5-AOI250039"><title>Conclusions</title><p>In this cohort study of pregnant individuals with OUD, we found that buprenorphine use in pregnancy was associated with improvements in pregnancy and infant outcomes, underscoring the need for OUD treatment expansion in the US.</p></sec></body><back><ref-list id="REF-AOI250039"><title>References</title><ref id="aoi250039r1"><label>1</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Haight</surname><given-names>SC</given-names></string-name>, <string-name name-style="western"><surname>Ko</surname><given-names>JY</given-names></string-name>, <string-name name-style="western"><surname>Tong</surname><given-names>VT</given-names></string-name>, <string-name name-style="western"><surname>Bohm</surname><given-names>MK</given-names></string-name>, <string-name name-style="western"><surname>Callaghan</surname><given-names>WM</given-names></string-name></person-group>. <article-title>Opioid use disorder documented at delivery hospitalization&#8212;United States, 1999-2014</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. <year>2018</year>;<volume>67</volume>(<issue>31</issue>):<fpage>845</fpage>-<lpage>849</lpage>. doi:<pub-id pub-id-type="doi">10.15585/mmwr.mm6731a1</pub-id><pub-id pub-id-type="pmid">30091969</pub-id><pub-id pub-id-type="pmcid">PMC6089335</pub-id></mixed-citation></ref><ref id="aoi250039r2"><label>2</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Hirai</surname><given-names>AH</given-names></string-name>, <string-name name-style="western"><surname>Ko</surname><given-names>JY</given-names></string-name>, <string-name name-style="western"><surname>Owens</surname><given-names>PL</given-names></string-name>, <string-name name-style="western"><surname>Stocks</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Patrick</surname><given-names>SW</given-names></string-name></person-group>. <article-title>Neonatal abstinence syndrome and maternal opioid-related diagnoses in the US, 2010-2017</article-title>. <source>JAMA</source>. <year>2021</year>;<volume>325</volume>(<issue>2</issue>):<fpage>146</fpage>-<lpage>155</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2020.24991</pub-id><pub-id pub-id-type="pmid">33433576</pub-id><pub-id pub-id-type="pmcid">PMC7804920</pub-id></mixed-citation></ref><ref id="aoi250039r3"><label>3</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Jarlenski</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Rothenberger</surname><given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Krans</surname><given-names>EE</given-names></string-name></person-group>. <article-title>Association of duration of methadone or buprenorphine use during pregnancy with risk of nonfatal drug overdose among pregnant persons with opioid use disorder in the US</article-title>. <source>JAMA Netw Open</source>. <year>2022</year>;<volume>5</volume>(<issue>4</issue>):<elocation-id>e227964</elocation-id>. doi:<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.7964</pub-id><pub-id pub-id-type="pmid">35438758</pub-id><pub-id pub-id-type="pmcid">PMC9020209</pub-id></mixed-citation></ref><ref id="aoi250039r4"><label>4</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Kaltenbach</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Berghella</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Finnegan</surname><given-names>L</given-names></string-name></person-group>. <article-title>Opioid dependence during pregnancy: effects and management</article-title>. <source>Obstet Gynecol Clin North Am</source>. <year>1998</year>;<volume>25</volume>(<issue>1</issue>):<fpage>139</fpage>-<lpage>151</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0889-8545(05)70362-4</pub-id><pub-id pub-id-type="pmid">9547764</pub-id></mixed-citation></ref><ref id="aoi250039r5"><label>5</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Jarlenski</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Krans</surname><given-names>EE</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>Q</given-names></string-name>, <etal/></person-group>. <article-title>Substance use disorders and risk of severe maternal morbidity in the United States</article-title>. <source>Drug Alcohol Depend</source>. <year>2020</year>;<volume>216</volume>:<elocation-id>108236</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2020.108236</pub-id><pub-id pub-id-type="pmid">32846369</pub-id><pub-id pub-id-type="pmcid">PMC7606664</pub-id></mixed-citation></ref><ref id="aoi250039r6"><label>6</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Wen</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Batista</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Wright</surname><given-names>JD</given-names></string-name>, <etal/></person-group>. <article-title>Postpartum readmissions among women with opioid use disorder</article-title>. <source>Am J Obstet Gynecol MFM</source>. <year>2019</year>;<volume>1</volume>(<issue>1</issue>):<fpage>89</fpage>-<lpage>98</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ajogmf.2019.02.004</pub-id><pub-id pub-id-type="pmid">33319760</pub-id></mixed-citation></ref><ref id="aoi250039r7"><label>7</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Logue</surname><given-names>TC</given-names></string-name>, <string-name name-style="western"><surname>Wen</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Friedman</surname><given-names>AM</given-names></string-name></person-group>. <article-title>Demographic trends associated with substance use disorder and risk for adverse obstetric outcomes with cannabis and opioid use disorders</article-title>. <source>J Matern Fetal Neonatal Med</source>. <year>2022</year>;<volume>35</volume>(<issue>26</issue>):<elocation-id>2128658</elocation-id>. doi:<pub-id pub-id-type="doi">10.1080/14767058.2022.2128658</pub-id><pub-id pub-id-type="pmid">36617462</pub-id></mixed-citation></ref><ref id="aoi250039r8"><label>8</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Maeda</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bateman</surname><given-names>BT</given-names></string-name>, <string-name name-style="western"><surname>Clancy</surname><given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>Creanga</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Leffert</surname><given-names>LR</given-names></string-name></person-group>. <article-title>Opioid abuse and dependence during pregnancy: temporal trends and obstetrical outcomes</article-title>. <source>Anesthesiology</source>. <year>2014</year>;<volume>121</volume>(<issue>6</issue>):<fpage>1158</fpage>-<lpage>1165</lpage>. doi:<pub-id pub-id-type="doi">10.1097/ALN.0000000000000472</pub-id><pub-id pub-id-type="pmid">25405293</pub-id></mixed-citation></ref><ref id="aoi250039r9"><label>9</label><mixed-citation publication-type="webpage">Opioid use and opioid use disorder in pregnancy. <person-group><collab>American College of Obstetricians and Gynecologists</collab></person-group>. August 2017. Accessed April 7, 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2017/08/opioid-use-and-opioid-use-disorder-in-pregnancy" ext-link-type="uri">https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2017/08/opioid-use-and-opioid-use-disorder-in-pregnancy</ext-link></mixed-citation></ref><ref id="aoi250039r10"><label>10</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Grossarth</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Osmundson</surname><given-names>SS</given-names></string-name>, <string-name name-style="western"><surname>Wiese</surname><given-names>AD</given-names></string-name>, <etal/></person-group>. <article-title>Maternal opioid use disorder and the risk of postneonatal infant mortality</article-title>. <source>JAMA Pediatr</source>. <year>2023</year>;<volume>177</volume>(<issue>7</issue>):<fpage>675</fpage>-<lpage>683</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamapediatrics.2023.1047</pub-id><pub-id pub-id-type="pmid">37155175</pub-id><pub-id pub-id-type="pmcid">PMC10167598</pub-id></mixed-citation></ref><ref id="aoi250039r11"><label>11</label><mixed-citation publication-type="webpage">Evidence-based, whole person care of pregnant people who have opioid use disorder. <person-group><collab>Substance Abuse and Mental Health Services Administration</collab></person-group>. May 2023. Accessed November 3, 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://store.samhsa.gov/product/advisory-evidence-based-whole-person-care-pregnant-people-who-have-opioid-use-disorder" ext-link-type="uri">https://store.samhsa.gov/product/advisory-evidence-based-whole-person-care-pregnant-people-who-have-opioid-use-disorder</ext-link></mixed-citation></ref><ref id="aoi250039r12"><label>12</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Link</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Miller</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Kaltenbach</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Seligman</surname><given-names>N</given-names></string-name></person-group>. <article-title>Buprenorphine-naloxone use in pregnancy: a systematic review and metaanalysis</article-title>. <source>Am J Obstet Gynecol MFM</source>. <year>2020</year>;<volume>2</volume>(<issue>3</issue>):<elocation-id>100179</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.ajogmf.2020.100179</pub-id><pub-id pub-id-type="pmid">33345863</pub-id></mixed-citation></ref><ref id="aoi250039r13"><label>13</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Walsh</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Preston</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Stitzer</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Cone</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Bigelow</surname><given-names>GE</given-names></string-name></person-group>. <article-title>Clinical pharmacology of buprenorphine: ceiling effects at high doses</article-title>. <source>Clin Pharmacol Ther</source>. <year>1994</year>;<volume>55</volume>(<issue>5</issue>):<fpage>569</fpage>-<lpage>580</lpage>. doi:<pub-id pub-id-type="doi">10.1038/clpt.1994.71</pub-id><pub-id pub-id-type="pmid">8181201</pub-id></mixed-citation></ref><ref id="aoi250039r14"><label>14</label><mixed-citation publication-type="webpage">Clinical guidance for treating pregnant and parenting women with opioid use disorder and their infants. <person-group><collab>Substance Abuse and Mental Health Services Administration</collab></person-group>. January 2018. Accessed October 30, 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://store.samhsa.gov/product/clinical-guidance-treating-pregnant-and-parenting-women-opioid-use-disorder-and-their" ext-link-type="uri">https://store.samhsa.gov/product/clinical-guidance-treating-pregnant-and-parenting-women-opioid-use-disorder-and-their</ext-link></mixed-citation></ref><ref id="aoi250039r15"><label>15</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Dick</surname><given-names>AW</given-names></string-name>, <string-name name-style="western"><surname>Pacula</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Gordon</surname><given-names>AJ</given-names></string-name>, <etal/></person-group>. <article-title>Growth in buprenorphine waivers for physicians increased potential access to opioid agonist treatment, 2002-11</article-title>. <source>Health Aff (Millwood)</source>. <year>2015</year>;<volume>34</volume>(<issue>6</issue>):<fpage>1028</fpage>-<lpage>1034</lpage>. doi:<pub-id pub-id-type="doi">10.1377/hlthaff.2014.1205</pub-id><pub-id pub-id-type="pmid">26056209</pub-id><pub-id pub-id-type="pmcid">PMC4743254</pub-id></mixed-citation></ref><ref id="aoi250039r16"><label>16</label><mixed-citation publication-type="webpage">Mainstreaming Addiction Treatment Act of 2021, S 445, 117th Cong (2021-2022). February 25, <year>2021</year>. Accessed October 30, 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.congress.gov/bill/117th-congress/senate-bill/445" ext-link-type="uri">https://www.congress.gov/bill/117th-congress/senate-bill/445</ext-link></mixed-citation></ref><ref id="aoi250039r17"><label>17</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Jones</surname><given-names>HE</given-names></string-name>, <string-name name-style="western"><surname>Kaltenbach</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Heil</surname><given-names>SH</given-names></string-name>, <etal/></person-group>. <article-title>Neonatal abstinence syndrome after methadone or buprenorphine exposure</article-title>. <source>N Engl J Med</source>. <year>2010</year>;<volume>363</volume>(<issue>24</issue>):<fpage>2320</fpage>-<lpage>2331</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1005359</pub-id><pub-id pub-id-type="pmid">21142534</pub-id><pub-id pub-id-type="pmcid">PMC3073631</pub-id></mixed-citation></ref><ref id="aoi250039r18"><label>18</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Suarez</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Huybrechts</surname><given-names>KF</given-names></string-name>, <string-name name-style="western"><surname>Straub</surname><given-names>L</given-names></string-name>, <etal/></person-group>. <article-title>Buprenorphine versus methadone for opioid use disorder in pregnancy</article-title>. <source>N Engl J Med</source>. <year>2022</year>;<volume>387</volume>(<issue>22</issue>):<fpage>2033</fpage>-<lpage>2044</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa2203318</pub-id><pub-id pub-id-type="pmid">36449419</pub-id><pub-id pub-id-type="pmcid">PMC9873239</pub-id></mixed-citation></ref><ref id="aoi250039r19"><label>19</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Krans</surname><given-names>EE</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>JY</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>Q</given-names></string-name>, <etal/></person-group>. <article-title>Outcomes associated with the use of medications for opioid use disorder during pregnancy</article-title>. <source>Addiction</source>. <year>2021</year>;<volume>116</volume>(<issue>12</issue>):<fpage>3504</fpage>-<lpage>3514</lpage>. doi:<pub-id pub-id-type="doi">10.1111/add.15582</pub-id><pub-id pub-id-type="pmid">34033170</pub-id><pub-id pub-id-type="pmcid">PMC8578145</pub-id></mixed-citation></ref><ref id="aoi250039r20"><label>20</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Patrick</surname><given-names>SW</given-names></string-name>, <string-name name-style="western"><surname>Dudley</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Martin</surname><given-names>PR</given-names></string-name>, <etal/></person-group>. <article-title>Prescription opioid epidemic and infant outcomes</article-title>. <source>Pediatrics</source>. <year>2015</year>;<volume>135</volume>(<issue>5</issue>):<fpage>842</fpage>-<lpage>850</lpage>. doi:<pub-id pub-id-type="doi">10.1542/peds.2014-3299</pub-id><pub-id pub-id-type="pmid">25869370</pub-id><pub-id pub-id-type="pmcid">PMC4411781</pub-id></mixed-citation></ref><ref id="aoi250039r21"><label>21</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Cooper</surname><given-names>WO</given-names></string-name>, <string-name name-style="western"><surname>Hernandez-Diaz</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Arbogast</surname><given-names>PG</given-names></string-name>, <etal/></person-group>. <article-title>Major congenital malformations after first-trimester exposure to ACE inhibitors</article-title>. <source>N Engl J Med</source>. <year>2006</year>;<volume>354</volume>(<issue>23</issue>):<fpage>2443</fpage>-<lpage>2451</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa055202</pub-id><pub-id pub-id-type="pmid">16760444</pub-id></mixed-citation></ref><ref id="aoi250039r22"><label>22</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Gray</surname><given-names>KE</given-names></string-name>, <string-name name-style="western"><surname>Wallace</surname><given-names>ER</given-names></string-name>, <string-name name-style="western"><surname>Nelson</surname><given-names>KR</given-names></string-name>, <string-name name-style="western"><surname>Reed</surname><given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Schiff</surname><given-names>MA</given-names></string-name></person-group>. <article-title>Population-based study of risk factors for severe maternal morbidity</article-title>. <source>Paediatr Perinat Epidemiol</source>. <year>2012</year>;<volume>26</volume>(<issue>6</issue>):<fpage>506</fpage>-<lpage>514</lpage>. doi:<pub-id pub-id-type="doi">10.1111/ppe.12011</pub-id><pub-id pub-id-type="pmid">23061686</pub-id><pub-id pub-id-type="pmcid">PMC3498497</pub-id></mixed-citation></ref><ref id="aoi250039r23"><label>23</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Freese</surname><given-names>KE</given-names></string-name>, <string-name name-style="western"><surname>Bodnar</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Brooks</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>McTIGUE</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Himes</surname><given-names>KP</given-names></string-name></person-group>. <article-title>Population-attributable fraction of risk factors for severe maternal morbidity</article-title>. <source>Am J Obstet Gynecol MFM</source>. <year>2020</year>;<volume>2</volume>(<issue>1</issue>):<elocation-id>100066</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.ajogmf.2019.100066</pub-id><pub-id pub-id-type="pmid">32864602</pub-id><pub-id pub-id-type="pmcid">PMC7450808</pub-id></mixed-citation></ref><ref id="aoi250039r24"><label>24</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Lazariu</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Nguyen</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>McNutt</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Jeffrey</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kacica</surname><given-names>M</given-names></string-name></person-group>. <article-title>Severe maternal morbidity: a population-based study of an expanded measure and associated factors</article-title>. <source>PLoS One</source>. <year>2017</year>;<volume>12</volume>(<issue>8</issue>):<elocation-id>e0182343</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0182343</pub-id><pub-id pub-id-type="pmid">28787028</pub-id><pub-id pub-id-type="pmcid">PMC5546569</pub-id></mixed-citation></ref><ref id="aoi250039r25"><label>25</label><mixed-citation publication-type="webpage">Opioid National Drug Code and oral MME conversion file update. <person-group><collab>Centers for Disease Control and Prevention</collab></person-group>. February 1, <year>2023</year>. Accessed April 7, 2025. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://archive.cdc.gov/www_cdc_gov/opioids/data-resources/index.html" ext-link-type="uri">https://archive.cdc.gov/www_cdc_gov/opioids/data-resources/index.html</ext-link></mixed-citation></ref><ref id="aoi250039r26"><label>26</label><mixed-citation publication-type="webpage">Identifying severe maternal morbidity (SMM). <person-group><collab>Centers for Disease Control and Prevention</collab></person-group>. May 15, <year>2024</year>. Accessed April 15, 2025. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/maternal-infant-health/php/severe-maternal-morbidity/" ext-link-type="uri">https://www.cdc.gov/maternal-infant-health/php/severe-maternal-morbidity/</ext-link></mixed-citation></ref><ref id="aoi250039r27"><label>27</label><mixed-citation publication-type="webpage">Rural-Urban Continuum Codes. <person-group><collab>US Department of Agriculture</collab></person-group>. Accessed April 18, 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ers.usda.gov/data-products/rural-urban-continuum-codes/" ext-link-type="uri">https://www.ers.usda.gov/data-products/rural-urban-continuum-codes/</ext-link></mixed-citation></ref><ref id="aoi250039r28"><label>28</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Thomas</surname><given-names>LE</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Pencina</surname><given-names>MJ</given-names></string-name></person-group>. <article-title>Overlap weighting: a propensity score method that mimics attributes of a randomized clinical trial</article-title>. <source>JAMA</source>. <year>2020</year>;<volume>323</volume>(<issue>23</issue>):<fpage>2417</fpage>-<lpage>2418</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2020.7819</pub-id><pub-id pub-id-type="pmid">32369102</pub-id></mixed-citation></ref><ref id="aoi250039r29"><label>29</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Howell</surname><given-names>EA</given-names></string-name></person-group>. <article-title>Reducing disparities in severe maternal morbidity and mortality</article-title>. <source>Clin Obstet Gynecol</source>. <year>2018</year>;<volume>61</volume>(<issue>2</issue>):<fpage>387</fpage>-<lpage>399</lpage>. doi:<pub-id pub-id-type="doi">10.1097/GRF.0000000000000349</pub-id><pub-id pub-id-type="pmid">29346121</pub-id><pub-id pub-id-type="pmcid">PMC5915910</pub-id></mixed-citation></ref><ref id="aoi250039r30"><label>30</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Geller</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Koch</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Garland</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>MacDonald</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Storey</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Lawton</surname><given-names>B</given-names></string-name></person-group>. <article-title>A global view of severe maternal morbidity: moving beyond maternal mortality</article-title>. <source>Reprod Health</source>. <year>2018</year>;<volume>15</volume>(<issue>1</issue>)(<supplement>suppl 1</supplement>):<fpage>98</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12978-018-0527-2</pub-id><pub-id pub-id-type="pmid">29945657</pub-id><pub-id pub-id-type="pmcid">PMC6019990</pub-id></mixed-citation></ref><ref id="aoi250039r31"><label>31</label><mixed-citation publication-type="webpage">Maternal infant health: preterm birth. <person-group><collab>Centers for Disease Control and Prevention</collab></person-group>. May 20, <year>2024</year>. Accessed October 21, 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/maternal-infant-health/preterm-birth/index.html" ext-link-type="uri">https://www.cdc.gov/maternal-infant-health/preterm-birth/index.html</ext-link></mixed-citation></ref><ref id="aoi250039r32"><label>32</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Henkhaus</surname><given-names>LE</given-names></string-name>, <string-name name-style="western"><surname>Buntin</surname><given-names>MB</given-names></string-name>, <string-name name-style="western"><surname>Henderson</surname><given-names>SC</given-names></string-name>, <string-name name-style="western"><surname>Lai</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Patrick</surname><given-names>SW</given-names></string-name></person-group>. <article-title>Disparities in receipt of medications for opioid use disorder among pregnant women</article-title>. <source>Subst Abus</source>. <year>2022</year>;<volume>43</volume>(<issue>1</issue>):<fpage>508</fpage>-<lpage>513</lpage>. doi:<pub-id pub-id-type="doi">10.1080/08897077.2021.1949664</pub-id><pub-id pub-id-type="pmid">34270396</pub-id><pub-id pub-id-type="pmcid">PMC8875287</pub-id></mixed-citation></ref><ref id="aoi250039r33"><label>33</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Muhar</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>McNeer</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Presley</surname><given-names>LD</given-names></string-name>, <etal/></person-group>. <article-title>Use of medications for opioid use disorder and child welfare outcomes</article-title>. <source>JAMA Health Forum</source>. <year>2024</year>;<volume>5</volume>(<issue>7</issue>):<elocation-id>e241768</elocation-id>. doi:<pub-id pub-id-type="doi">10.1001/jamahealthforum.2024.1768</pub-id><pub-id pub-id-type="pmid">38995635</pub-id><pub-id pub-id-type="pmcid">PMC11245717</pub-id></mixed-citation></ref><ref id="aoi250039r34"><label>34</label><mixed-citation publication-type="webpage"><person-group><string-name name-style="western"><surname>West</surname><given-names>KD</given-names></string-name>, <string-name name-style="western"><surname>Ali</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Henke</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Head</surname><given-names>MA</given-names></string-name></person-group>. Opioid use treatment of pregnant/postpartum women and their children. <person-group><collab>Office of the Assistant Secretary for Planning and Evaluation</collab></person-group>. September 23, <year>2024</year>. Accessed October 18, 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://aspe.hhs.gov/reports/opioid-use-treatment-pregnant-postpartum-women-children" ext-link-type="uri">https://aspe.hhs.gov/reports/opioid-use-treatment-pregnant-postpartum-women-children</ext-link></mixed-citation></ref><ref id="aoi250039r35"><label>35</label><mixed-citation publication-type="webpage">Provisional drug overdose data. <person-group><collab>National Center for Health Statistics</collab></person-group>. October 10, <year>2024</year>. Accessed November 3, 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm" ext-link-type="uri">https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm</ext-link></mixed-citation></ref><ref id="aoi250039r36"><label>36</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Kariisa</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Davis</surname><given-names>NL</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Vital signs: drug overdose deaths, by selected sociodemographic and social determinants of health characteristics&#8212;25 states and the District of Columbia, 2019-2020</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. <year>2022</year>;<volume>71</volume>(<issue>29</issue>):<fpage>940</fpage>-<lpage>947</lpage>. doi:<pub-id pub-id-type="doi">10.15585/mmwr.mm7129e2</pub-id><pub-id pub-id-type="pmid">35862289</pub-id><pub-id pub-id-type="pmcid">PMC9310633</pub-id></mixed-citation></ref><ref id="aoi250039r37"><label>37</label><mixed-citation publication-type="webpage">Data and statistics. <person-group><collab>Tennessee Department of Health</collab></person-group>. Accessed November 4, 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.tn.gov/health/health-program-areas/fhw/maternal-mortality-review/data-and-statistics.html" ext-link-type="uri">https://www.tn.gov/health/health-program-areas/fhw/maternal-mortality-review/data-and-statistics.html</ext-link></mixed-citation></ref><ref id="aoi250039r38"><label>38</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Patrick</surname><given-names>SW</given-names></string-name>, <string-name name-style="western"><surname>Richards</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Dupont</surname><given-names>WD</given-names></string-name>, <etal/></person-group>. <article-title>Association of pregnancy and insurance status with treatment access for opioid use disorder</article-title>. <source>JAMA Netw Open</source>. <year>2020</year>;<volume>3</volume>(<issue>8</issue>):<elocation-id>e2013456</elocation-id>. doi:<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.13456</pub-id><pub-id pub-id-type="pmid">32797175</pub-id><pub-id pub-id-type="pmcid">PMC7428808</pub-id></mixed-citation></ref><ref id="aoi250039r39"><label>39</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Davis</surname><given-names>CS</given-names></string-name>, <string-name name-style="western"><surname>McNeer</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Patrick</surname><given-names>SW</given-names></string-name></person-group>. <article-title>Laws forbidding pregnancy discrimination in substance use disorder treatment are not associated with treatment access</article-title>. <source>J Addict Med</source>. <year>2022</year>;<volume>16</volume>(<issue>3</issue>):<fpage>364</fpage>-<lpage>367</lpage>. doi:<pub-id pub-id-type="doi">10.1097/ADM.0000000000000897</pub-id><pub-id pub-id-type="pmid">34282081</pub-id><pub-id pub-id-type="pmcid">PMC8761200</pub-id></mixed-citation></ref><ref id="aoi250039r40"><label>40</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Bruzelius</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Martins</surname><given-names>SS</given-names></string-name></person-group>. <article-title>US trends in drug overdose mortality among pregnant and postpartum persons, 2017-2020</article-title>. <source>JAMA</source>. <year>2022</year>;<volume>328</volume>(<issue>21</issue>):<fpage>2159</fpage>-<lpage>2161</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2022.17045</pub-id><pub-id pub-id-type="pmid">36472602</pub-id><pub-id pub-id-type="pmcid">PMC9856503</pub-id></mixed-citation></ref></ref-list><notes notes-type="supplementary-material" id="note-AOI250039-1"><supplementary-material id="note-AOI250039-1-s" position="float" content-type="local-data" orientation="portrait"><label>Supplement 1.</label><caption><p><bold>eTable 1.</bold> List of Opioid Use Disorder and Neonatal Opioid Withdrawal Syndrome Diagnoses ICD-9-CM and ICD-10-CM Codes</p><p><bold>eFigure 1.</bold> Conceptual Model of Opioid Use Disorder and Adverse Maternal-Infant Dyadic Outcomes</p><p><bold>eTable 2.</bold> Buprenorphine NDC</p><p><bold>eFigure 2.</bold> Refining buprenorphine exposure with Medicaid Pharmacy Claims</p><p><bold>eTable 3.</bold> List of Severe Maternal Morbidity ICD-9-CM and ICD-10-CM Codes</p><p><bold>eTable 4.</bold> List of Hepatitis C, Maternal Mental Health, and Substance Use Diagnoses ICD-9-CM and ICD-10-CM Codes</p><p><bold>eFigure 3.</bold> Love Plot Demonstrating Covariate Balance Between the Treated and Untreated Groups With and Without Inverse Probability and Overlap Weighting, 20 Weeks Gestation to 6 Weeks Postpartum</p><p><bold>eFigure 4.</bold> Love Plot Demonstrating Covariate Balance Between the Treated and Untreated Groups With and Without Inverse Probability and Overlap Weighting, 90 Days Before Birth to 6 Weeks Postpartum</p><p><bold>eTable 5.</bold> Characteristics of Maternal-Infant Dyads with Opioid Use Disorder Based Upon Receipt of Medications for Opioid Use Disorder, Tennessee 2010-2021, 20 Weeks Gestation to 6 Weeks Postpartum</p><p><bold>eTable 6.</bold> Characteristics of Maternal-Infant Dyads with Opioid Use Disorder Based Upon Receipt of Medications for Opioid Use Disorder, Tennessee 2010-2021, 90 Days Before Birth to 6 Weeks Postpartum</p><p><bold>eFigure 5.</bold> Percentage of Adverse Pregnancy Outcomes Among Pregnant People with Opioid Use Disorder, Tennessee 2010-2021, 20 Weeks Gestation to 6 Weeks Postpartum</p><p><bold>eFigure 6.</bold> Percentage of Adverse Pregnancy Outcomes Among Pregnant People with Opioid Use Disorder, Tennessee 2010-2021, 90 Days Before Birth to 6 Weeks Postpartum</p><p><bold>eTable 7.</bold> Unadjusted Adverse Pregnancy Outcomes by Receipt of Medications for Opioid Use Disorder 90 Days Before Birth to 6 Weeks Postpartum, Tennessee 2010-2021</p><p><bold>eTable 8.</bold> Severe Maternal Morbidity Indicators Among Pregnant People with Opioid Use Disorder by Receipt of Medication for Opioid Use Disorder 90 Days Before Birth to 6 Weeks Postpartum, Tennessee 2010-2021</p><p><bold>eFigure 7.</bold> Association of Buprenorphine Treatment with Adverse Pregnancy Outcomes Among Pregnant People with Opioid Use Disorder After Applying Propensity Scores with Overlap Weights in 20 Week Cohort, Tennessee 2010-2021</p><p><bold>eFigure 8.</bold> Association of Buprenorphine Treatment with Adverse Pregnancy Outcomes Among Pregnant People with Opioid Use Disorder After Applying Propensity Scores with Overlap Weights in 90 Day Cohort, Tennessee 2010-2021</p><p><bold>eTable 9.</bold> Association of Buprenorphine Treatment with Adverse Pregnancy Outcomes Among Pregnant People with Opioid Use Disorder Applying Propensity Scores with Overlap Weights in 20 Week Cohort</p><p><bold>eTable 10.</bold> Association of Buprenorphine Treatment with Adverse Pregnancy Outcomes Among Pregnant People with Opioid Use Disorder Applying Propensity Scores with Overlap Weights in 90 Day Cohort, Tennessee 2010-2021</p><p><bold>eFigure 9.</bold> Association of Timing of Buprenorphine Treatment with Adverse Pregnancy Outcomes Among Pregnant People with Opioid Use Disorder Treated with Buprenorphine After Applying Propensity Scores with Overlap Weights in 20 Week Cohort, Tennessee 2010-2021</p><p><bold>eTable 11.</bold> Association of Timing of Buprenorphine Treatment with Adverse Pregnancy Outcomes Among Pregnant People with Opioid Use Disorder Treated with Buprenorphine Applying Propensity Scores with Overlap Weights in 20 Week Cohort, Tennessee 2010-2021</p><p><bold>eFigure 10.</bold> Association of Timing of Buprenorphine Treatment with Adverse Pregnancy Outcomes Among Pregnant People with Opioid Use Disorder Treated with Buprenorphine After Applying Propensity Scores with Overlap Weights in 90 Day Cohort, Tennessee 2010-2021</p><p><bold>eTable 12.</bold> Association of Timing of Buprenorphine Treatment with Adverse Pregnancy Outcomes Among Pregnant People with Opioid Use Disorder Treated with Buprenorphine Applying Propensity Scores with Overlap Weights in 90 Day Cohort, Tennessee 2010-2021</p><p><bold>eFigure 11.</bold> Association of Buprenorphine Treatment with Birth Hospitalization Length of Stay Among Pregnant People with Opioid Use Disorder After Applying Propensity Scores with Overlap Weights, Tennessee 2010-2021</p><p><bold>eTable 13.</bold> Association of Timing of Buprenorphine Treatment with Birth Hospitalization Length of Stay Among Pregnant People with Opioid Use Disorder Applying Propensity Scores with Overlap Weights, Tennessee 2010-2021</p><p><bold>eFigure 12.</bold> Logistic Regression Analysis of Association of Days Supply of Buprenorphine with Adverse Pregnancy Outcomes Among Pregnant People with Opioid Use Disorder Treated with Buprenorphine in 20 Week Cohort, Tennessee 2010-2021</p><p><bold>eFigure 13.</bold> Logistic Regression Analysis of Association of Days Supply of Buprenorphine with Adverse Pregnancy Outcomes Among Pregnant People with Opioid Use Disorder Treated with Buprenorphine in 90 Day Cohort, Tennessee 2010-2021</p><p><bold>eFigure 14.</bold> Logistic Regression Analysis of Association of Average Daily Dose of Buprenorphine with Adverse Pregnancy Outcomes Among Pregnant People with Opioid Use Disorder Treated with Buprenorphine in 20 Week Cohort, Tennessee 2010-2021</p><p><bold>eFigure 15.</bold> Logistic Regression Analysis of Association of Average Daily Dose of Buprenorphine with Adverse Pregnancy Outcomes Among Pregnant People with Opioid Use Disorder Treated with Buprenorphine in 90 Day Cohort, Tennessee 2010-2021</p><p><bold>eFigure 16.</bold> Cohort Construction Flow Diagram</p><p><bold>eTable 14.</bold> Descriptive Statistics Comparing Pregnant People with Opioid Use Disorder Alone, Buprenorphine Alone, Opioid Use Disorder and Buprenorphine</p><p><bold>eFigure 17.</bold> Love Plot, Limiting Sample to Pregnant People Diagnosed with Opioid Use Disorder with and without Buprenorphine</p><p><bold>eTable 15.</bold> Association of Buprenorphine Treatment with Adverse Pregnancy Outcomes Among Pregnant People with Opioid Use Disorder After Applying Propensity Scores with Overlap Weights Restricted to Diagnoses of OUD, Tennessee 2010-2021</p><p><bold>eTable 16.</bold> Number Needed to Treat Calculations for Key Outcomes in Primary Analysis</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jamahealthforum-e251814-s001.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material position="float" content-type="local-data" orientation="portrait"><label>Supplement 2.</label><caption><p>
Data Sharing Statement
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jamahealthforum-e251814-s002.pdf" position="float" orientation="portrait"/></supplementary-material></notes></back></article></pmc-articleset>